Prospects for gene therapy of haemophilia

被引:40
作者
Nathwani, AC
Davidoff, AM
Tuddenham, EGD
机构
[1] UCL, Dept Haematol, London WC1E 6HX, England
[2] St Jude Childrens Res Hosp, Dept Surg, Memphis, TN 38105 USA
[3] Hammersmith Hosp, Imperial Coll, MRC Thrombosis & Haemostasis Res, London, England
关键词
gene therapy; haemophilia; insertional mutagenesis;
D O I
10.1111/j.1365-2516.2004.00926.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
That gene therapy offers the promise of a cure for haemophilia was apparent more than a decade ago. After years of failure, substantial progress in the efficiency of gene transfer technology has recently resulted in impressive success in animal models with haemophilia. However, fears of the risks intrinsic to such therapy have been raised by the fate of two children cured of immune deficiency by gene transfer who have, however, subsequently developed leukaemia as a result of insertional mutagenesis. The purpose of this review is to outline the current status of gene therapy in light of recent successes and tragedies and to consider the prospects for curing haemophilia in the short-to-medium term.
引用
收藏
页码:309 / 318
页数:10
相关论文
共 50 条
[21]   Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity [J].
Lozier, JN ;
Metzger, ME ;
Donahue, RE ;
Morgan, RA .
BLOOD, 1999, 94 (12) :3968-3975
[22]   AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B [J].
Manno, CS ;
Chew, AJ ;
Hutchison, S ;
Larson, PJ ;
Herzog, RW ;
Arruda, VP ;
Tai, SJ ;
Ragni, MV ;
Thompson, A ;
Ozelo, M ;
Couto, LB ;
Leonard, DGB ;
Johnson, FA ;
McClelland, A ;
Scallan, C ;
Skarsgard, E ;
Flake, AW ;
Kay, MA ;
High, KA ;
Glader, B .
BLOOD, 2003, 101 (08) :2963-2972
[23]  
Mannucci Pier M, 2002, Hematology Am Soc Hematol Educ Program, P1
[24]   Medical progress - The hemophilias - From royal genes to gene therapy [J].
Mannucci, PM ;
Tuddenham, EGD .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (23) :1773-1779
[25]   High-level factor VIII gene expression in vivo achieved by nonviral liver-specific gene therapy vectors [J].
Miao, CH ;
Ye, X ;
Thompson, AR .
HUMAN GENE THERAPY, 2003, 14 (14) :1297-1305
[26]   Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo [J].
Miao, CH ;
Thompson, AR ;
Loeb, K ;
Ye, X .
MOLECULAR THERAPY, 2001, 3 (06) :947-957
[27]   Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer [J].
Mingozzi, F ;
Liu, YL ;
Dobrzynski, E ;
Kaufhold, A ;
Liu, JH ;
Wang, YQ ;
Arruda, VR ;
High, KA ;
Herzog, RW .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) :1347-1356
[28]   Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector [J].
Mingozzi, F ;
Schüttrumpf, J ;
Arruda, VR ;
Liu, YH ;
Liu, YL ;
High, KA ;
Xiao, WD ;
Herzog, RW .
JOURNAL OF VIROLOGY, 2002, 76 (20) :10497-10502
[29]   Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy [J].
Mount, JD ;
Herzog, RW ;
Tillson, DM ;
Goodman, SA ;
Robinson, N ;
McCleland, ML ;
Bellinger, D ;
Nichols, TC ;
Arruda, VR ;
Lothrop, CD ;
High, KA .
BLOOD, 2002, 99 (08) :2670-2676
[30]   AAV serotype 2 vectors preferentially integrate into active genes in mice [J].
Nakai, H ;
Montini, E ;
Fuess, S ;
Storm, TA ;
Grompe, M ;
Kay, MA .
NATURE GENETICS, 2003, 34 (03) :297-302